Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05766839 · ClinicalTrials.gov registry record · Phase 2
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
A Phase 2 study of Hyperkalemia, sponsored by Vifor Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT05766839 is a Phase 2 study of Hyperkalemia that is actively recruiting participants, run by Vifor Pharma. The registered enrollment target is 32 participants, below the 58-participant average among 8 other Hyperkalemia trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05766839, a Phase 2 study of Hyperkalemia, is actively recruiting participants, sponsored by Vifor Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
Conditions Studied
Interventions
- DRUG Patiromer
Study Locations (20)
Other
- Monash Medical Centre Clayton - Clayton
- The Royal Children's Hospital (RCH) - Parkville
- Children's Hospital Westmead Centre for Kidney Research - Westmead
- Universitair Ziekenhuis Gent - Ghent
- UZ Leuven - Leuven
- Helsingin Yliopistollinen Keskussairaala Uusi Lastensairaala - Helsinki
- CHRU Montpellier - Arnaud de Villeneuve - Montpellier
Florida
- UF Health Pediatric Multispecialty Center Site - Jacksonville
- Miller School of Medicine, University of Miami - Miami
- Arnold Palmer Hospital for Children - Orlando
North Carolina
- Duke University Hospital & Medical Center - Durham
- Duke University Hospital - Durham
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Augusta University - Children's Hospital of Georgia - Augusta
Illinois
- University of Illinois College of Medicine - Peoria
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-04-06 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05766839
The ClinicalTrials.gov registry entry for NCT05766839 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 8 other Hyperkalemia trials with a reported enrollment target (45% lower). The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperkalemia appearing as the primary indexed condition, and to 1 intervention - of which Patiromer is the first listed.
NCT05766839 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05766839 about?
NCT05766839 is a clinical study titled "Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age". A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
What is the current status of trial NCT05766839?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-04-06. Estimated completion is 2030-12-01.
What conditions does trial NCT05766839 study?
This clinical trial studies the following conditions: Hyperkalemia.
What interventions are being tested in trial NCT05766839?
The interventions under investigation include: Patiromer (DRUG).
Who is sponsoring clinical trial NCT05766839?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05766839 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperkalemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
COMPLETED · Phase 2
-
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
COMPLETED · Phase 2
-
Evaluation of Patiromer in Heart Failure Patients
COMPLETED · Phase 2
-
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
RECRUITING
-
Adding Urea to the Final Dialysis Fluid
RECRUITING · Phase 1
-
Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.